Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. (Q38891877)

7 September 2017

Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. (English)

1 reference

7 September 2017

2

Hagop Kantarjian

1 reference

7 September 2017

4

Farhad Ravandi

1 reference

7 September 2017

6

Naval Daver

1 reference

7 September 2017

1

Lucia Masarova

1 reference

7 September 2017

5

Padmanee Sharma

1 reference

7 September 2017

Guillermo Garcia-Mannero

series ordinal

3

1 reference

PubMed ID

28321813

7 September 2017

language of work or name

English

0 references

publication date

1 January 2017

1 reference

Advances in Experimental Medicine and Biology

7 September 2017

1 reference

7 September 2017

995

1 reference

7 September 2017

73-95

1 reference

Outcome of patients with acute myelogenous leukemia after second salvage therapy

7 September 2017

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Monoclonal antibodies for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Numbers and cytotoxicities of CD3+CD56+ T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Gemtuzumab ozogamicin: time to resurrect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Neural cell adhesion molecule (NCAM) is the antigen recognized by monoclonal antibodies of similar specificity in small-cell lung carcinoma and neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

ADME of antibody-maytansinoid conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Bispecific T-cell engaging antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Adoptive cell transfer as personalized immunotherapy for human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

CD28z CARs and armored CARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Deciphering and reversing tumor immune suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Next generation of immunotherapy for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Enhancing SIV-specific immunity in vivo by PD-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Restoring function in exhausted CD8 T cells during chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Immune modulation in cancer with antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

ICOS: a new costimulatory ligand/receptor pair and its role in T-cell activion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34(+) progenitor cells during differentiation into antigen presenting cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Immune regulation by 4-1BB and 4-1BBL: complexities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Therapy for elderly patients with acute myeloid leukemia: a problem in search of solutions

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Monoclonal antibody therapy of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

31 March 2020

DARTs take aim at BiTEs

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

Expression of co-stimulatory molecules on acute myeloid leukaemia blasts may effect duration of first remission

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-53156-4_4

10.1007/978-3-319-53156-4_4

31 March 2020

Identifiers

DOI

1 reference

7 September 2017

1 reference

PubMed ID

28321813